SYNG
from 399 today
Syngene reported a big quarterly miss with revenue declining 15.8% YoY, impacted by lack of Librela supplies to Zoetis and discovery client attrition, leading to a guidance cut to mid-single digit revenue decline for FY27. We retain our Reduce rating with a revised target price of Rs405 based on an unchanged 35x FY28E EPS.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
